Maryna Marynchenko

Attention-Deficit/Hyperactivity Disorder: Increased Costs for Patients and Their Families

OBJECTIVE To estimate the direct (medical and prescription drug) and indirect (work loss) costs of children treated for attention-deficit/hyperactivity disorder (ADHD) and their family members. METHOD The data source was an administrative database from a national, Fortune 100 manufacturer that included all medical, pharmaceutical, and disability claims for beneficiaries (n > 100,000). The analysis involved four samples. The ADHD patient sample included individuals age 18 or younger with at least one ADHD claim during the study period (1996-1998). Resource utilization of ADHD patients was contrasted with a matched control sample of patients who did not have claims for ADHD. The ADHD and non-ADHD family samples included non-ADHD family members of ADHD patients and their matched controls. RESULTS The annual average expenditure (direct cost) per ADHD patient was

Societal cost of rheumatoid arthritis patients in the US.

1,574, compared to

Economic Implications of Treatment-Resistant Depression Among Employees

541 among matched controls. The annual average payment (direct plus indirect cost) per family member was

Pulmonary Medication Adherence and Health-care Use in Cystic Fibrosis

2,728 for non-ADHD family members of ADHD patients versus

Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs

1,440 for family members of matched controls. Both patient and family cost differences were significant at the 95% confidence level. CONCLUSIONS ADHD imposes a significant financial burden regarding the cost of medical care and work loss for patients and family members.

Employees with overactive bladder: Work loss burden

Abstract Objective: To estimate comprehensive cost of rheumatoid arthritis (RA) patients to society and individual stakeholders, including patients/employees, employers, family members/caregivers, and government. Research design and methods: Administrative claims databases covering privately insured and Medicare and Medicaid beneficiaries in the US were used to compute the excess payer and beneficiary-paid costs per patient with RA compared with matched controls. Similarly, per-person excess costs for caregivers and uninsured patients with RA were estimated. Costs were estimated for other burdens, including costs of work-loss to employers, adaptations to home and work environments, lost on-the-job productivity, informal and hired care/household help, and job turnover costs. Intangible costs associated with quality-of-life deterioration were estimated based on legal system jury awards, whereas costs for premature mortality were based on lifetime earnings data. Per-capita cost estimates were weighted by the relevant population to estimate societal costs. Because data were incomplete, several assumptions were required; these assumptions could lead to an over- or under-estimation of cost burdens. Results: Annual excess health care costs of RA patients were

Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population

8.4 billion, and costs of other RA consequences were

Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase

10.9 billion. These costs translate to a total annual cost of

Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout

19.3 billion. From a stakeholder perspective, 33% of the total cost was allocated to employers, 28% to patients, 20% to the government, and 19% to caregivers. Adding intangible costs of quality-of-life deterioration (

Economic Impact of Therapeutic Substitution of a Brand Selective Serotonin Reuptake Inhibitor with an Alternative Generic Selective Serotonin Reuptake Inhibitor in Patients with Major Depressive Disorder

10.3 billion) and premature mortality (